Wednesday, February 10, 2010, 12:24PM AEST - The Australian Stockmarket closes in 3 hours and 41 minutes.
To create a watchlist or portfolio of shares, Register

Imarx Therapeutics, Inc. (IMRX.OB)

On Feb 6: 0.018 USD   0.00 (0.00%)  
 MORE ON IMRX.OB 
Quotes
HereSummary
Charts
Technical Analysis
News & Info
Company
Analyst Coverage
Ownership
Financials
 IMARX THERAPEUTICS (OTC BB:IMRX.OB) Delayed quote dataEdit
Last Trade:0.018 USD
Trade Time:Feb 6
Change: 0.00 (0.00%)
Prev Close:0.018
Open:N/A
Bid:0.015 x 5000
Ask:0.018 x 5000
1y Target Est:1.00
Day's Range:N/A - N/A
52wk Range:N/A
Volume:0
Avg Vol (3m):N/A
Market Cap:209.97K
P/E (ttm):N/A
EPS (ttm):-0.058
Div & Yield: (N/A%)
[Chart]
1d  5d
 Add IMRX.OB to Portfolio   Download Data

 HEADLINES 
IMARX THERAPEUTICS INC Financials
EDGAR Online Financials (Wed, Nov 25)
IMARX THERAPEUTICS INC Files SEC form 10-Q, Quarterly Report
EDGAR Online (Tue, Nov 17)
IMARX THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers
EDGAR Online (Sat, Sep 19)
IMARX THERAPEUTICS INC Files SEC form 8-K, Other Events
EDGAR Online (Wed, Sep 9)
IMARX THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition
EDGAR Online (Tue, Aug 11)
ImaRx Therapeutics Reports Second Quarter Ended 2009 Financial Results
GlobeNewswire (Tue, Aug 11)
IMARX THERAPEUTICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events
EDGAR Online (Sat, Jun 20)
IMARX THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition
EDGAR Online (Fri, May 15)
ImaRx Therapeutics Reports First Quarter Ended 2009 Financial Results
GlobeNewswire (Fri, May 15)
IMARX THERAPEUTICS INC Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial Statements and Ex
EDGAR Online (Tue, May 12)
More Headlines for IMRX.OB...

 ANALYST 
EPS Est (next year) (Dec-08) :N/A
EPS Est (in 2 years) (Dec-10) :N/A
Avg Rec (current)*:2.0
PEG Ratio:N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
ImaRx Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on the development of therapies for stroke and other vascular disorders, using its microbubble technology.

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
Latest News7 Indices